Clinical Trials
Below are current clinical trials.
269 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The overall aim of this study is to evaluate the clinical utility of the QuantiFERON-CMV test in solid organ transplant recipients on CMV prophylaxis to predict development of CMV disease after completion of prophylaxis. Our hypothesis is that in CMV D+/R- solid organ transplant recipients, the development of immunity as measured by a positive QuantiFERON CMV assay will predict a lower risk of CMV disease after prophylaxis is completed.
-
Jacksonville, Fla.
The purpose of this study is to evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 1 or 4 hepatitis C virus (HCV) infection. Participants will be randomized to receive 12 or 24 weeks of dosing with the LDV/SOF FDC tablet+ribavirin (RBV).
-
Scottsdale/Phoenix, Ariz.
This open-label study will evaluate safety, pharmacokinetics and efficacy of a 12 or 24 week regimen of ombitasvir/ABT-450/ritonavir and dasabuvir with or without ribavirin in HCV-genotype 1-infected subjects with an Estimated Glomerular Filtration Rate (eGFR) <30, including those on hemodialysis.
-
Rochester, Minn.
The purpose of this study is to assess short- and long-term clinical outcomes and immune responses after SARS-CoV-2 infection and/or MIS-C in children (defined as individuals who have not yet reached their 21st birthday). Participants will be identified through active recruitment measures within hospitals and through ambulatory and laboratory-based databases of SARS-CoV-2 positive children.
-
Rochester, Minn.
The purpose of this study is to determine differences in microbiota composition in volunteers with and without Rome IV defined Campylobacter jejuni PI-IBS, and to determine differences in peripheral metabolites, proteins and lipids in volunteers with and without Rome IV defined Campylobacter jejuni PI-IBS.
-
Rochester, Minn.
The objectives of this study are to describe the incidence of COVID-related olfactory loss, to compare the effectiveness of acupuncture, steroid rinses, and olfactory training versus steroid rinses and olfactory training in the treatment of COVID-related olfactory loss, and to recommend a treatment paradigm for patients with COVID-related olfactory loss.
-
Rochester, Minn.
The purpose of this study is to identify correlates of healthcare-seeking behavior in patients with ACS and CHF and its association with psychosocial and health outcomes.
-
Rochester, Minn.
Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19.
Phase 3: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19.
-
Jacksonville, Fla.
This will be a prospective study of patients with IBD at Mayo Clinic initially in Jacksonville with possible subsequent extension to other Mayo sites. We will evaluate the immunogenicity of commercially available COVID-19 vaccines and compare vaccine response among the groups based on their immunosuppressive regimens. We will divide the immunosuppressive regimens into presumed high vaccine responders Group A and presumed low vaccine responders Group B. We will also assess for adverse reactions to the vaccine and compare with the reported rates in the clinical trials that led to approval of these vaccines.
-
Jacksonville, Fla., Rochester, Minn.
The primary objective of this study is to evaluate the clinical effectiveness of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.